|File Size:||593 kb|
|File Size:||207 kb|
ERA Biology A pioneer in products for invasive fungal disease diagnosis. Products include Aspergillus galactomannan, Beta-D-Glucan,and Cryptococcal capsular polysaccharide in automated CLSI, LFA, EIA & PCR formats.
MICRONAUT Broth microdilution is the technique that should be used for antifungal susceptibility according to EUCAST. This product has been evaluated and is in use in leading UK hospitals.
LDBIO The National Aspergillosis Centre in Manchester, UK has tested their LFA device for Aspergillus antibody and found it to be accurate, identifying 91% of cases of Chronic Pulmonary Aspergillosis in 30min.
COVID-19 associated invasive aspergillosis: data from the UK National Mycology Reference Laboratory. From the discussion 'In addition to radiological imaging, serial screening for CAPA (CoVID Associated Pulmonary Aspergillosis) in ICU patients with deteriorating respiratory function should include: (i) regular (at least weekly) Aspergillus antigen testing of serum samples, (ii) regular (at least weekly) BDG testing of serum samples , (iii) Aspergillus antigen testing of BAL fluids (where available) or non -directed lavages/tracheal aspirates and (iv) Aspergillus PCR in conjunction with conventional mycological examination (microscopy and culture) of respiratory secretions if available. '
Invasive fungal disease occurs often in critically ill patients with COVID-19 on mechanical ventilation, according to a study published in Clinical Infectious Diseases.
A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU
Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA)
Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
'The use of Aspergillus IgG antibody as a diagnostic tool is far superior to the use of Aspergillus precipitins and should always be used as the gold standard ..to confirm infection.'
J. Fungi 2016, 2(2), 18; https://doi.org/10.3390/jof2020018
Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis
The LDBIO Aspergillus ICT IgG-IgM immunochromatographic technology (ICT) test was compared with Aspergillus IgG titers in CPA patients, measured by ImmunoCAP-specific IgG assays (cutoff value, 40 mg of antigen-specific antibodies [mgA]/liter For proven CPA patients versus controls, sensitivity and specificity for the LDBio Aspergillus ICT were 91.6% and 98.0%, respectively. In contrast, the routinely used ImmunoCAP assay exhibited 80.5% sensitivity for the same cohort
Of the 154 patients in our CPA case group, 108 had precipitins testing (for Aspergillus antibody) performed as part of routine diagnostics, with 57.4% sensitivity.
Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis.
Early recognition and diagnosis of allergic bronchopulmonary aspergillosis (ABPA) is critical
to improve patient symptoms, and antifungal therapy may prevent or delay progression of
bronchiectasis and development of chronic pulmonary aspergillosis.
ABPA and control sera collected at the National Aspergillosis Centre (Manchester, UK) and/or from the Manchester Allergy, Respiratory and Thoracic Surgery research biobank were evaluated using the Aspergillus ICT assay. Results were read both visually and digitally (using a lateral flow reader). Serological Aspergillus-specific IgG and IgE, and total IgE titres were measured by ImmunoCAP.
. The test effectively distinguished between Aspergillus-sensitization complicating asthma and/or bronchiectasis, and underlying conditions. It is rapid (result in <30 minutes) and easy to perform, with simple result interpretation by visible inspection. Overall, the LDBio Aspergillus ICT exhibits excellent performance as a screening tool in the ABPA diagnostic pathway
Published: September 25, 2020 https://doi.org/10.1371/journal.pone.0238855